These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Rehabilitation of erectile function following radical prostatectomy. McCullough AR Asian J Androl; 2008 Jan; 10(1):61-74. PubMed ID: 18087645 [TBL] [Abstract][Full Text] [Related]
4. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Kovanecz I; Rambhatla A; Ferrini M; Vernet D; Sanchez S; Rajfer J; Gonzalez-Cadavid N Int J Impot Res; 2008; 20(2):202-12. PubMed ID: 17882231 [TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction. Axilrod AC Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309 [TBL] [Abstract][Full Text] [Related]
7. Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors. El-Sakka AI Expert Opin Investig Drugs; 2011 Oct; 20(10):1305-9. PubMed ID: 21846259 [TBL] [Abstract][Full Text] [Related]
11. Gene therapy and erectile dysfunction: the current status. Lau DH; Kommu SS; Siddiqui EJ; Thompson CS; Morgan RJ; Mikhailidis DP; Mumtaz FH Asian J Androl; 2007 Jan; 9(1):8-15. PubMed ID: 16888683 [TBL] [Abstract][Full Text] [Related]
12. Local therapies to heal the penis: fact or fiction? Kim ED J Androl; 2009; 30(4):384-90. PubMed ID: 19023141 [TBL] [Abstract][Full Text] [Related]
13. Strategies to promote recovery of cavernous nerve function after radical prostatectomy. Burnett AL World J Urol; 2003 May; 20(6):337-42. PubMed ID: 12811492 [TBL] [Abstract][Full Text] [Related]
14. The evolving role of testosterone in the treatment of erectile dysfunction. Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550 [TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 5 mechanisms and therapeutic applications. Burnett AL Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563 [TBL] [Abstract][Full Text] [Related]
16. Penile rehabilitation following radical prostatectomy: role of early intervention and chronic therapy. Zippe CD; Pahlajani G Urol Clin North Am; 2007 Nov; 34(4):601-18, viii. PubMed ID: 17983900 [TBL] [Abstract][Full Text] [Related]
17. Pharmacology of erectile dysfunction in man. Cirino G; Fusco F; Imbimbo C; Mirone V Pharmacol Ther; 2006 Aug; 111(2):400-23. PubMed ID: 16443277 [TBL] [Abstract][Full Text] [Related]
18. The role of vacuum erection devices in penile rehabilitation after radical prostatectomy. Lehrfeld T; Lee DI Int J Impot Res; 2009; 21(3):158-64. PubMed ID: 19225465 [TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase type 5 in men with vasculogenic and post-radical prostatectomy erectile dysfunction: is there a molecular difference? Karakus S; Musicki B; Burnett AL BJU Int; 2018 Dec; 122(6):1066-1074. PubMed ID: 29888556 [TBL] [Abstract][Full Text] [Related]
20. The effect of erectile function on the use of phosphodiesterase-5 inhibitors after radical prostatectomy in Japanese and U.S. men. Namiki S; Kwan L; Kagawa-Singer M; Arai Y; Litwin MS Urology; 2008 May; 71(5):901-5. PubMed ID: 18374396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]